Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay ...

The 4-dose KwikPen device supports weight reduction in patients with obesity or overweight with weight-related conditions.

The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”), the global leader in science-backed weight management, today announced a pharmacy ...

Eli Lilly and Walmart have partnered to offer in-store pickup of Zepbound (tirzepatide) single-dose vials through the LillyDirect platform by mid-November. The collaboration marks the first time ...

Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for ...

Discover the latest updates on the weight loss drug market, including Lilly's Zepbound, Hims & Hers, and NovoNordisk's price cuts.